{
    "nctId": "NCT05470348",
    "briefTitle": "A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",
    "officialTitle": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Phase Ia: Dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Sign the informed consent voluntarily and follow the program requirements;\n* 2. No gender limitation;\n* 3. Age: \u226518 years old and \u226475 years old (Stage Ia); \u226518 years old (Ib);\n* 4. Expected survival time \u22653 months;\n* 5. Failure or intolerance to standard treatment confirmed by histopathology and/or cytology or no standard treatment currently available or unresectable locally advanced or metastatic breast cancer and other solid tumors for which standard treatment is not available;\n* 6. Agree to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic tumor within 3 years; If subjects are unable to provide tumor tissue samples, they will be admitted after evaluation by the investigator if other admission criteria are met.\n* 7. Must have at least one measurable lesion as defined by RECIST V1.1;\n* 8. ECOG score of 0 or 1;\n* 9. Toxicity from previous antitumor therapy has returned to level \u22641 as defined by NCI-CTCAE V5.0\n* 10. No serious cardiac dysfunction, left ventricular ejection fraction \u226550%;\n* 11. Organ function level must meet the following requirements and meet the following standards: A) Bone marrow function: absolute neutrophil count (ANC) \u22651.5\u00d710\\^9/L, platelet count \u2265100\u00d710\\^9/L, hemoglobin \u226590 g/L; B) Liver function: total bilirubin (TBIL\u22641.5 ULN), AST and ALT \u22642.5ULN in patients without liver metastasis, AST and ALT \u22645.0 ULN in patients with liver metastasis; C) Renal function: Creatinine (Cr) \u22641.5 ULN, or creatinine clearance (Ccr) \u226550 mL/min.\n* 12. Coagulation function: International standardized ratio (INR) \u22641.5, and activated partial thrombin time (APTT) \u22641.5ULN;\n* 13. Urinary protein \u22642+ or \u22641000mg/24h;\n* 14. For premenopausal women who are likely to have children, a pregnancy test must be performed within 7 days of the start of treatment. Serum or urine pregnancy must be negative and must be non-lactation; All enrolled patients (male and female) should use adequate barrier contraception throughout the treatment cycle and 6 months after the end of treatment.\n\nExclusion Criteria:\n\n* 1. Prior treatment with ADC drugs using camptothecin derivatives (topoisomerase I inhibitors) as toxins;\n* 2. Use of chemotherapy, biotherapy, immunotherapy, radical radiotherapy, major surgery (as defined by the investigator), targeted therapy (including small molecule tyrosine kinase inhibitors) and other antitumor therapies within 4 weeks or 5 half-lives, whichever is less, prior to initial dosing; Mitomycin and nitrosourea were administered within 6 weeks prior to initial administration; Fluorouracil oral agents such as ticio, capecitabine, oral endocrine therapy, or palliative radiotherapy within 2 weeks before initial administration;\n* 3. History of severe heart disease, such as symptomatic congestive heart failure (CHF) \u22652 (CTCAE 5.0), Heart failure (NYHA) \u22652, history of transmural myocardial infarction, unstable angina, etc\n* 4. QT prolongation (male QTc \\> 450 msec or female QTc \\> 470 msec), complete left bundle branch block, III atrioventricular block;\n* 5. Active autoimmune and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, are excluded from type I sugars urinary diseases, hypothyroidism that can be controlled only by alternative therapy, skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis);\n* 6. Other malignant tumors were diagnosed within 2 years prior to first administration, except for radical basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radical resected carcinoma in situ;\n* 7. Hypertension poorly controlled by two antihypertensive medications (systolic blood pressure \\& GT; 150 mmHg or diastolic pressure \\& GT; 100 mmHg);\n* 8. Lung disease defined as grade \u22652 according to CTCAE V5.0, and now defined according to RTOG/EORTC Grade \u22651 radiation pneumonia; Existing patients with interstitial lung disease (ILD);\n* 9. Screening for unstable thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism requiring therapeutic intervention within the first 6 months; Infusion device-related thrombosis is excluded;\n* 10. Primary central nervous system (CNS) malignancy; Patients with CNS metastasis who have failed local treatment (excluding asymptomatic BMS, or those with stable clinical symptoms and no steroid or other treatment for BMS for \u226528 days);\n* 11. Patients with uncontrolled pleural and abdominal effusion with clinical symptoms, judged by the investigator to be unsuitable for inclusion;\n* 12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipient component of BL-B01D1;\n* 13. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (ALLO-HSCT);\n* 14. Cumulative dose of anthracyclines \\> 360 mg/m\\^2 in previous anthracyclines (new) adjuvant therapy\n* 15. Positive human immunodeficiency virus antibody (HIVAb), active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \\> 10\\^3IU/ml) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \\> lower limit of detection);\n* 16. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.\n* 17. Participated in another clinical trial within 4 weeks prior to initial administration (starting from the time of last administration);\n* 18. Other conditions considered inappropriate for participation in this clinical trial by the investigator",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}